OUH - Clinical trials

Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, Eustace A (2024)
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
Acta Oncol, 63, 213-219
DOI 10.2340/1651-226X.2024.24179, PubMed 38647024

Brativnyk A, Ankill J, Helland Å, Fleischer T (2024)
Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma
Int J Cancer (in press)
DOI 10.1002/ijc.34915, PubMed 38489486

Haakensen VD, Öjlert ÅK, Thunold S, Farooqi S, Nowak AK, Chin WL, Grundberg O, Szejniuk WM, Cedres S, Sørensen JB, Dalen TS, Lund-Iversen M, Bjaanæs M, Helland Å (2024)
UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial
Eur J Cancer, 202, 113973
DOI 10.1016/j.ejca.2024.113973, PubMed 38447379

More publications


Durvalumab (MEDI4736) After chemoRadioTherapy for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients More information	Nivolumab and Ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma – a phase II randomised clinical and translational trial More information
	NorPACT-2
Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer (COM-IT-2) – a phase II randomised clinical and translational trial More information	Norwegian Pancreatic Cancer Trial (NorPACT)-2: Liquid biopsies and blood-based biomarkers (https://www.ous-research.no/ pancreaticcancer)

NorPACT-2